Prognostic significance of autoimmunity during treatment of melanoma with interferon

• Published in: Seminars in immunopathology Vol. 33; no. 4; pp. 385 - 391
• Main Authors: Krauze, Michal T., Tarhini, Ahmad, Gogas, Helen, Kirkwood, John M.
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer-Verlag 01.07.2011; Springer Nature B.V
• Subjects: Autoimmunity - drug effects; Biomedical and Life Sciences; Biomedicine; Cancer therapies; Cytokines; Disease; Drug dosages; Humans; Immune system; Immunology; Immunotherapy; Interferon; Interferons - therapeutic use; Internal Medicine; Lymphocytes; Melanoma; Melanoma - diagnosis; Melanoma - drug therapy; Melanoma - immunology; Metastasis; Mutation; Prognosis; Review; Skin cancer; T cell receptors; Toxicity; Treatment Outcome; Ultraviolet radiation; Young adults; United States > US; Pittsburgh Pennsylvania; Autoimmunity; Interferon; Melanoma; High-dose interferon; Cancer
• ISSN: 1863-2297; 1863-2300; 1863-2300
• DOI: 10.1007/s00281-011-0247-y

Since the pivotal cooperative group trials in the 1980’s-90’s,, high-dose interferon (HDI) has been the standard of adjuvant therapy. Despite multiple other trials evaluating potential new therapies in melanoma, HDI remains the only FDA-approved therapy for stage IIB and III melanoma. Initial reports from the more recent phase III international trials of modifications of the original HDI regimen linked the appearance of autoimmunity with improved outcomes of disease. Trials of high-dose interleukin-2, many years earlier, reported anecdotal observations that were consistent with the hypothesis that autoimmunity and clinical benefit of immunotherapies of melanoma are linked with one another. The only prospectively conducted study examining the appearance of clinical and laboratory evidence of autoimmunity during HDI therapy was published by Gogas and colleagues, demonstrating statistically significant impact on relapse-free survival and overall survival. Retrospectively conducted studies of different intermediate dosage regimens of interferon (IFN) have not fully confirmed the linkage of serological evidence of autoimmunity and improved survival outcomes. With the emergence of new immunotherapies in treatment of melanoma, this review highlights the importance of autoimmunity for future applications in melanoma and reviews significant differences of past studies evaluating the appearance of autoimmunity during IFN therapy in high-risk melanoma.